儿童期多发性硬化症的治疗：现状、挑战与机遇
Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.
作者信息
Margoni Monica, Rinaldi Francesca, Perini Paola, Gallo Paolo
机构信息
Multiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, Italy.
Padova Neuroscience Centre, University of Padua, Padua, Italy.
出版信息
Front Neurol. 2021 May 17;12:676095. doi: 10.3389/fneur.2021.676095. eCollection 2021.
Abstract
Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.
摘要
儿童多发性硬化症（POMS）的治疗是根据观察性研究以及从成人多发性硬化症（AOMS）患者临床试验中获得的数据进行调整的。用于AOMS的新型治疗药物越来越多，其中许多也将在POMS中进行正式研究。然而，在儿童和年轻患者使用这些疗法的有效性和安全性存在重要问题。本综述将讨论POMS治疗的当前技术水平，并将重点关注新型疗法（口服和注射用疾病修正药物）以及目前仍在研究中的疗法。
相似文献
1
Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.儿童期多发性硬化症的治疗：现状、挑战与机遇
Front Neurol. 2021 May 17;12:676095. doi: 10.3389/fneur.2021.676095. eCollection 2021.
2
Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.儿童起病型多发性硬化症的新型治疗方法
Curr Treat Options Neurol. 2019 Sep 27;21(10):50. doi: 10.1007/s11940-019-0592-z.
3
Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies.儿童多发性硬化症的长期治疗策略，包括疾病修正疗法的应用。
Children (Basel). 2019 May 31;6(6):73. doi: 10.3390/children6060073.
4
Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.儿童期和成人期发病多发性硬化症患者生活质量的决定因素。
Neurology. 2020 Mar 3;94(9):e932-e941. doi: 10.1212/WNL.0000000000008667. Epub 2019 Nov 15.
5
Update on pediatric-onset multiple sclerosis.儿童发病多发性硬化症的最新进展。
Rev Neurol (Paris). 2018 Jun;174(6):398-407. doi: 10.1016/j.neurol.2018.04.003. Epub 2018 May 19.
6
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis.在那他珠单抗之后使用阿仑单抗，对成人起病型多发性硬化症的疗效比对儿童起病型多发性硬化症更好。
Ther Adv Neurol Disord. 2023 Oct 6;16:17562864231177196. doi: 10.1177/17562864231177196. eCollection 2023.
7
Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS).芬戈莫德治疗复发缓解型多发性硬化症（RRMS）儿科患者的安全性、有效性及耐受性综述
Pediatric Health Med Ther. 2019 Nov 12;10:141-146. doi: 10.2147/PHMT.S220817. eCollection 2019.
8
Treatment of multiple sclerosis in children: A brief overview.儿童多发性硬化症的治疗：简要概述。
Clin Immunol. 2022 Apr;237:108947. doi: 10.1016/j.clim.2022.108947. Epub 2022 Feb 2.
9
Narrative review based on fingolimod therapy in pediatric MS.基于芬戈莫德治疗儿童多发性硬化症的叙述性综述。
SAGE Open Med. 2023 May 8;11:20503121231171996. doi: 10.1177/20503121231171996. eCollection 2023.
10
Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis.儿童期起病的多发性硬化症成年患者的认知及患者报告结局
Mult Scler. 2016 Mar;22(3):354-61. doi: 10.1177/1352458515588781. Epub 2015 Jun 3.
引用本文的文献
1
A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.一项多中心、前瞻性、随机、开放标签的实用性试验，旨在比较干扰素β-1a和醋酸格拉替雷对患有多发性硬化症的儿科患者的有效性和安全性。
Neurol Sci. 2025 Aug 8. doi: 10.1007/s10072-025-08377-3.
2
Age-Onset-Related Particularities of Pediatric MS-Understanding the Spectrum: A Tertiary Center Experience.儿童多发性硬化症与年龄相关的特殊性：理解疾病谱——来自三级医疗中心的经验
Diseases. 2025 Jun 25;13(7):193. doi: 10.3390/diseases13070193.
3
Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies.推进儿童多发性硬化症的治疗：B细胞靶向疗法的前景
Int J Mol Sci. 2025 Jun 22;26(13):5989. doi: 10.3390/ijms26135989.
4
Pediatric-Onset Multiple Sclerosis (POMS) and Epilepsy: Exploring Etiological Complexity-Outcomes from a Single-Center Experience.儿童期起病的多发性硬化症（POMS）与癫痫：探索病因复杂性——来自单中心经验的结果
Children (Basel). 2025 May 14;12(5):631. doi: 10.3390/children12050631.
5
Identifying Cladribine prescription pattern in MS: an Italian multicentre study.确定多发性硬化症中克拉屈滨的处方模式：一项意大利多中心研究。
Ther Adv Neurol Disord. 2025 Jan 8;18:17562864241304212. doi: 10.1177/17562864241304212. eCollection 2025.
6
The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series.奥法木单抗治疗儿童抗N-甲基-D-天冬氨酸受体脑炎：病例系列
Heliyon. 2024 Nov 23;10(23):e40680. doi: 10.1016/j.heliyon.2024.e40680. eCollection 2024 Dec 15.
7
Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach.小儿多发性硬化症治疗的新旧策略：一种新治疗方法的个人观点
Neurol Ther. 2024 Aug;13(4):949-963. doi: 10.1007/s40120-024-00633-6. Epub 2024 Jun 1.
8
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.基于注册登记研究的比较：那他珠单抗、芬戈莫德和注射用药物在儿童发病多发性硬化症中的疗效。
Neurology. 2024 Apr 9;102(7):e208114. doi: 10.1212/WNL.0000000000208114. Epub 2024 Mar 6.
9
Multiple sclerosis under the age of ten: the challenge of a rare diagnosis in a special population - a case series.10岁以下的多发性硬化症：特殊人群中罕见诊断的挑战——病例系列
Front Neurosci. 2023 Dec 20;17:1297171. doi: 10.3389/fnins.2023.1297171. eCollection 2023.
10
The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries.多发性硬化症治疗的治疗价值：对三个欧洲国家卫生技术评估的分析。
Front Pharmacol. 2023 Apr 28;14:1169400. doi: 10.3389/fphar.2023.1169400. eCollection 2023.
本文引用的文献
1
Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis.缓释富马酸二甲酯在复发缓解型多发性硬化症儿科患者中的安全性和有效性
Front Neurol. 2021 Jan 4;11:606418. doi: 10.3389/fneur.2020.606418. eCollection 2020.
2
Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic.在SARS-CoV-2大流行期间，那他珠单抗治疗儿童多发性硬化症的安全性。
Mult Scler J Exp Transl Clin. 2020 Oct 12;6(4):2055217320966346. doi: 10.1177/2055217320966346. eCollection 2020 Oct-Dec.
3
Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic.加拿大一所大学多发性硬化症诊所中接受阿仑单抗治疗的儿科多发性硬化症患者的短期疗效。
Mult Scler J Exp Transl Clin. 2020 Jul 1;6(2):2055217320926613. doi: 10.1177/2055217320926613. eCollection 2020 Apr-Jun.
4
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.利妥昔单抗在儿科多发性硬化症和其他 CNS 脱髓鞘疾病患者中的应用：实际考虑。
Mult Scler. 2021 Oct;27(12):1814-1822. doi: 10.1177/1352458520932798. Epub 2020 Jun 19.
5
Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.真实世界中初始疾病修正疗法在儿科多发性硬化症中的疗效。
Ann Neurol. 2020 Jul;88(1):42-55. doi: 10.1002/ana.25737. Epub 2020 May 14.
6
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG study.芬戈莫德对儿童发病多发性硬化症患者 MRI 结局的影响：来自 3 期 PARADIG 研究的结果。
J Neurol Neurosurg Psychiatry. 2020 May;91(5):483-492. doi: 10.1136/jnnp-2019-322138. Epub 2020 Mar 4.
7
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.儿童发病多发性硬化症患者延迟治疗对残疾的长期影响：一项前瞻性丹麦队列研究。
Mult Scler Relat Disord. 2020 May;40:101956. doi: 10.1016/j.msard.2020.101956. Epub 2020 Jan 17.
8
Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.儿童期和成人期发病多发性硬化症患者生活质量的决定因素。
Neurology. 2020 Mar 3;94(9):e932-e941. doi: 10.1212/WNL.0000000000008667. Epub 2019 Nov 15.
9
No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab.在接受那他珠单抗治疗的初诊小儿多发性硬化症患者中，未观察到疾病活动的证据（包括认知功能）（NEDA-3 加）。
J Neurol. 2020 Jan;267(1):100-105. doi: 10.1007/s00415-019-09554-z. Epub 2019 Sep 27.
10
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis.在高活性儿童多发性硬化症中，那他珠单抗之后使用阿仑单抗。
Mult Scler J Exp Transl Clin. 2019 Sep 16;5(3):2055217319875471. doi: 10.1177/2055217319875471. eCollection 2019 Jul-Sep.
Zotero 插件